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ABSTRACT
Purpose: To compare severity of visual field (VF) loss at first presentation in glaucoma clinics in
England and Tanzania.
Methods: Large archives of VF records from automated perimetry were used to retrospectively
examine vision loss at first presentation in glaucoma clinics in Tanzania (N = 1,502) and England
(N = 9,264). Mean deviation (MD) of the worse eye at the first hospital visit was used as an
estimate of detectable VF loss severity.
Results: In Tanzania, 44.7% {CI95%: 42.2, 47.2} of patients presented with severe VF loss (< −20 dB),
versus 4.6% {4.1, 5.0} in England. If we consider late presentation to also include cases of
advanced loss (-12.01 dB to -20 dB), then the proportion of patients presenting late was 58.1%
{55.6, 60.6} and 14.0% {13.3, 14.7}, respectively. The proportion of late presentations was greater in
Tanzania at all ages, but the difference was particularly pronounced among working-age adults,
with 50.3% {46.9, 53.7} of 18–65-year-olds presenting with advanced or severe VF loss, versus
10.2% {9.3, 11.3} in England. In both countries, men were more likely to present late than women.
Conclusions: Late presentation of glaucoma is a problem in England, and an even greater
challenge in Tanzania. Possible solutions are discussed, including increased community eye-
care, and a more proactive approach to case finding through the use of disruptive new technol-
ogies, such as low-cost, portable diagnostic aids.
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Introduction
Glaucoma is the third leading cause of blindness world-
wide, affecting approximately 3.5% of adults aged
40–80 years old.1 Glaucoma prevalence is even higher
in Africa (4.8%), where the number of cases is expected
to almost double from 10.3 to 19.1 million people
between 2020 and 2040.2 If untreated, glaucoma leads
to progressive, irreversible loss of visual function. It is
therefore important to detect cases early – or at least to
prevent people presenting with advanced loss.
Currently, however, the detection of glaucoma often
occurs late. For example, in England3,4,5, Canada6, and
Australia7, it is estimated that as many as one in five
patients with glaucomatous visual field (VF) loss already
has advanced damage in at least one eye by the time they
first present to a glaucoma clinic. The problem is likely
to be even greater in Sub-Saharan Africa where primary
eye care services are more sparsely distributed. For
example, a large population-based study in Nigeria
found that in 682 people with glaucoma, 94.4% were
unaware that they had the condition.8 Furthermore,
one in five of these individuals was already blind (visual
acuity <3/60 in better eye), with the main cause attribu-
table to glaucoma. Similarly, a prospective study of gov-
ernment-run glaucoma clinics in Botswana found that
one in seven individuals was blind at presentation (visual
acuity <3/60 in better eye).9 This suggests that not only is
glaucoma prevalent in Sub-Saharan Africa, but that the
problem is compounded by late presentation. Other
studies suggest the problem of late presentation may be
even worse. For example, one prominent review of glau-
coma in Sub-Saharan Africa estimated that “up to 50% of
cases [are] already blind in one eye at presentation”10,
and similar figures have been reported in individual
studies from across the continent (for a recent summary,
see Abdull et al., 201511)
In many of these previous studies, however, severity
at presentation has been characterized by visual acuity
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alone: a relatively crude measure of glaucomatous sight
loss (i.e., which primarily affects peripheral vision).
Unlike in Europe and elsewhere3–7, we know of no
studies that have conducted a detailed analysis of VF
loss at presentation, or which have examined how VF
loss varies with age, sex, or in defect pattern. Such
quantitative data on late presentation are needed for
developing appropriate public health policies and inter-
ventions: particularly those targeted at earlier disease
detection. There have also been no attempts to directly
compare the severity of VF loss at presentation between
countries in Sub-Saharan Africa and more affluent
nations. A like-for-like comparison would be helpful
for understanding the extent to which the late presen-
tation of glaucoma is a particular challenge in Sub-
Saharan Africa, versus a more general problem globally.
In the present study, we used retrospective data to
compare disease severity, as estimated by VF loss, in
patients attending hospital glaucoma clinics in Tanzania
and England. Large-scale data from standard automated
perimetry (SAP) were extracted from the electronic med-
ical records of routine clinical practices. Only data from
patients’ first appointment (and their worse eye) were
analyzed, in order to examine the detectable level of
glaucomatous VF loss at presentation. The hypothesis
was that the proportion of cases detected late (with
advanced or severe VF loss) would be greater in
Tanzania. We also used demographic data to study asso-
ciations of age and sex on late presentation.
Methods
Tanzania dataset
VF data were extracted retrospectively from the electronic
medical records (2009–2017) of Kilimanjaro Christian
Medical Centre’s Department of Ophthalmology: a large
referral and training institution in Northern Tanzania.
Basic demographic information (sex, age at time of test)
were also extracted. Only patients with test data for both
eyes and a recorded clinical diagnosis of glaucoma were
included. Patients with additional ophthalmic conditions
recorded (e.g., pseudophakia or early-cataract) were
included in the reported data, but the overall pattern of
results was unchanged if these individuals were removed
(see Supplemental Material 1).
The raw dataset contained a total of 10,286 VFs,
recorded on the Humphrey Visual Field Analyzer (HFA,
Carl Zeiss Meditec, Dublin, CA, USA). The study eye for
each patient was defined as the eye with the worse (more
negative) HFA mean deviation (MD) at the first clinic
visit. MD is a summary measure of VF loss, relative to
age-similar population norms, with more negative values
indicating greater overall VF loss. The worse eye was
selected as a surrogate measure of the ‘detectable’ level
of glaucomatous VF loss. This yielded 1,502 VFs, each
pertaining to the first examination of a single individual
(worse eye only).
Data extraction and analysis took place in 2018, and
was approved by the Research Ethics Committee of the
Kilimanjaro Christian Medical University College.
England dataset
VF data were extracted retrospectively from the
Medisoft databases (Medisoft Ltd., Leeds, UK)
used in three regional glaucoma clinics
(Cheltenham General Hospital Gloucestershire Eye
Unit, N = 50,144 examinations; Queen Alexandra
Hospital in Portsmouth, N = 31,879 examinations;
and The Calderdale and Huddersfield NHS
Foundation Trust Hospital, N = 70,955 examina-
tions). These data were recorded between 1989
and 2012, and data extraction took place in 2012
as described previously.12 Recorded clinical diag-
noses of glaucoma were not available, so as
a proxy (and to remove possible false-positive refer-
rals), patients were only included if they attended
three or more appointments at the glaucoma clinic;
although, as in the Tanzania dataset, only the data
from the very first appointment are reported. This
dataset yielded 9,264 records with the same format
as the Tanzania dataset (one record per person;
worse eye only; first appointment only). Data access
was granted by the Caldicott Guardian at each
center. Subsequent analyses of the data were
approved by a research ethics committee of City,
University of London. This study adhered to the
Declaration of Helsinki.
VF testing protocol
There were no differences in VF testing protocol
between the four testing sites (1 × Tanzania, 3 ×
England). All sites used the same hardware
(Humphrey Visual Field Analyzer), provided the
same information to patients prior to testing, and
administered the test in accordance with the manu-
facturer’s recommendations, with a trained techni-
cian present throughout. All testing was performed
using a Goldmann size III stimulus, a 24–2 test
pattern, and the Swedish Interactive Testing
Algorithm (SITA Standard or SITA Fast).
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Quantifying the severity of detectable sight loss
VF loss in the worse eye, quantified by MD, was used as
a measure of detectable sight loss. In accordance with
established criteria13, VF loss was categorized as Early
(MD better than −5 dB), Moderate (MD −5.01 to −12
dB), Advanced (MD −12.01 dB to −20 dB), or Severe (MD
−20.01 dB or worse). Alternative methods for staging VF
loss severity have been developed (e.g., the Enhanced
Glaucoma Severity Staging System.14) However, the use
of these more complex methods did not change the pre-
sent findings, so these data are reported in the
Supplemental Material only (Supplemental Material 2).
Analysis
Data were analyzed in MATLAB R2016a (The
MathWorks, Natick, USA). Severity of VF loss was ana-
lyzed by examining distributions of MD (a continuous
variable), and also by computing the proportion of indi-
viduals falling into each stage of VF loss severity (see
previous). Confidence intervals for key statistics were
derived using bootstrapping (N = 20,000; bias-
corrected and accelerated method). Individual visual
fields were plotted for inspection using custom
MATLAB software which we have made freely available
online (https://github.com/petejonze/VfPlot). Crude
Relative Risk ratios were computed to examine the asso-
ciation between late presentation (advanced or severe
VF loss) and age, sex, or country. For example, to com-
pute the association with sex, the data were stratified by
age (decades) and country (England, Tanzania). Relative
Risk was then calculated as the ratio of the proportion of
men to the proportion of women presenting with
advanced or severe VF loss (<−12 dB). RR is expected
to have a value of one under the null hypothesis that men
and women are equally affected by late presentation of
glaucoma. An overall age-standardized RR was calcu-
lated using Monte Carlo sampling.
Results
Overall
As shown in Figure 1, average VF loss at first presenta-
tion was greater in Tanzania than England (Median MD
{Quartiles}: −15.7 {-6.9, −29.0} vs −3.4 {-1.2, −7.7} dB;
Mann–Whitney U-test: P ≪ 0.001). Furthermore,
a greater proportion of individuals exhibited severe loss
(Percent {CI95}; Tanzania: 44.7% {42.2, 47.2} vs England:
4.6% {4.1, 5.0}). This corresponds to a Relative Risk ratio
for presenting with severe visual field loss in Tanzania of
9.8 {CI95: 8.8, 11.0}. In England, the proportion of late
presentations was lower than in Tanzania, but still sub-
stantial. For example, 14.0% {CI95: 13.3, 14.7} of new
patients exhibited advanced or severe VF loss, compared
to 58.1% {55.6, 60.6} in Tanzania.
High levels of late presentation in Tanzania are also
evident in Figure 2, which shows data from individual
eyes: systematically selected to show a representative
sample of VF loss severities within each population
(see Figure Legend for details regarding selection pro-
cess). From these data, it can be further seen that the
spatial distribution of VF loss was heterogeneous across
Early
Moderate
Advanced
Severe
Figure 1. Histograms showing VF loss severity at first presentation, for new glaucoma patients in Tanzania (left) and England (right).
Numbers show the proportion of individuals with early (≥ −5 dB), moderate (−5.01 dB to −12 dB), advanced (−12.01 dB to −20 dB),
or severe (< −20 dB) VF loss in their worse eye.
12 P. R. JONES ET AL.
individuals, but that the most common pattern of early
field-loss in both populations was a loss of vision in
peripheral superior and/or nasal regions (for further
spatial analyses, see Supplemental Material 3).
Age
The age of patients at first presentation was distributed
similarly in Tanzania and England (see Figure 3a),
although median age was 3.8 years lower in the
Tanzanian population (Median {CI95}: Tanzania: 63.0
{62.4, 64.0}; England: 66.8 {66.6, 67.0}). At almost all ages,
however, the proportion of individuals presenting with
advanced or severe VF loss was greater in Tanzania (see
Figure 3a–b).
In both countries, the majority of individuals pre-
senting with advanced or severe VF loss were aged 60+
years (Tanzania: 66%; England: 76%). However, among
younger patients, the proportion of individuals present-
ing late in Tanzania increased steadily, from 24% at age
10 to 58% at age 60 (Figure 3b, blue curve). In contrast,
the proportion of individuals exhibiting advanced or
severe loss in England was similar to Tanzania at child-
hood (25% at aged 10), but then declined to 8% by age
60 (Figure 3b, red curve). This trend difference meant
that younger, working-age adults in Tanzania were
disproportionately likely to present late, versus their
Figure 2. VF data for a representative sample of individuals (worse eye only). In both datasets, 41 individuals were sampled
uniformly from 0th, 2.5th, 5th, …, 100th percentile of VF loss severity (MD). The bottom right panel (grey square) shows the average
field of all patients at their first appointment (worse eye only; all eyes converted to left-eye format before mean-averaging values,
pointwise, across all individuals). Note the greater number of individuals presenting with severe VF loss in Tanzania, but also that
some eyes in the England cohort exhibited substantial VF loss.
a b
Figure 3. VF loss severity at first presentation as a function of age. (a) Histograms. In both datasets, patient ages followed similar
(‘gumbel max’) distributions (blue dashed lines), though the median age was older in the England population (67 vs. 63 years). (b)
Proportion of individuals with advanced loss, as a function of age. Lines indicate least-square polynomial spline fits to the data (NB:
the point marked with the black cross was not included in this fit).
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peers in England: Overall, 50.3% {46.9, 53.7} of adults
of prime working age (18–65 years) presented with
advanced or severe VF loss in Tanzania, compared to
10.2% {9.3, 11.3} in England. This corresponds to
a Relative Risk ratio for late presentation (advanced
or severe VF loss) of 4.9 {4.4, 5.6} for 18–65-year-
olds, compared to 4.3 {4.0, 4.6} for individuals age 65+.
Sex
In Tanzania, a greater proportion of men presented with
advanced or severe VF loss than women. As detailed in
Table 1, this effect was significant for the dataset as
a whole, and also for all individual age-groups between
40 and 70 years. Above 70 years, there was no significant
effect of sex, with similar proportions of VF loss in men
and women. In England, there was a similar sex difference
overall, and, as reported previously4, men between ages
60–80 were particularly more likely than women to pre-
sent with advanced or severe VF loss (see Table 1).
Discussion
The data show that in Tanzania, 45% of the people
presented to glaucoma clinics with severe visual field
(VF) loss in at least one eye, compared to 5% in
England. If we consider late presentation to include
also cases of advanced loss, then the proportion of
patients is even greater: 58%, and 14%, respectively.
Given the increased personal and economic costs
associated with irreversible VF loss15,16, such high
proportions of late presentation highlight the urgent
need for earlier detection of glaucoma in both
countries, but particularly in Tanzania. Of particular
concern is the high proportion of VF loss observed
among Tanzanian adults of prime working age
(18–65 years), with 50.3% presenting with advanced
or severe VF loss in one eye, versus 10.2% in
England. Visual impairments in younger adults are
particularly costly to society, making glaucoma detec-
tion in younger adults a particularly critical challenge
in Tanzania.
Comparison to previous data
The high proportion of severe VF loss at presentation
in Tanzania is consistent with previous studies of glau-
coma across Africa.17-25 For example, one prominent
review of glaucoma in Africa estimated that “up to 50%
of cases [are] already blind in 1 eye at presentation”10;
a value consistent with the 45% of individuals exhibit-
ing severe (<−20 dB) VF loss in the present study.
It has also been suggested previously that glaucoma
onset may occur at an earlier age in some African
populations.18,26 However, while the median age of
the Tanzania patients was somewhat lower (63 vs 67
years), the most striking difference was not the age of
the patients, but the high proportions of severe visual
field loss observed at all ages by the time people pre-
sented for treatment.
The greater proportion of late presentation in men
mirrors similar reports in the UK4 and elsewhere27, and
the effect was similar in magnitude across both Tanzania
and England. This may in part reflect the well-established,
universal tendency for men to delay seeking medical
help.28 It may also reflect an increased prevalence of
primary open-angle glaucoma in men29, although the
data supporting this sex difference are currently
inconclusive.30 Finally, the greater proportion of late pre-
sentation in men may also represent some women failing
to enter the healthcare system altogether. For example,
women in rural regions of Sub-Saharan Africa are parti-
cularly likely to be disadvantaged in terms of education,
transport, and income31, all of which are key factors that
mediate health-seeking behaviors (see C. Late presenta-
tion: Causes and Solutions, below). Ultimately, further
research is required to establish causal factors, including
population-based prospective studies.
Concerns and limitations
One potential concern with the present study is that the
differences observed between Tanzania and England may
be due to differences in how the tests were explained or
administered. However, the same protocol was followed
across all sites, and there was no substantive change in
Table 1. Proportion of individuals with advanced or severe
VF loss (< −12 dB) at first presentation as a function of
sex, and corresponding crude risk ratios for being male.
Asterisks highlight in which the sex effect was statistically
significant (CI95 > 1). For the rationale behind the use of
crude risk ratios, and details regarding how they were
computed, see Crabb, Saunders, & Edwards (2017).4 Ages
below 40 years are not included due to insufficient data.
Rates of late presentation by Age and Sex
Age, years Men Women Relative Risk (CI95)
Tanzania
40–50 58.2% (n = 46) 38.2% (n = 21) 1.53 (1.07–2.35)
50–60 56.2% (n = 95) 44.0% (n = 62) 1.28 (1.02–1.62)
60–70 63.0% (n = 150) 52.6% (n = 90) 1.20 (1.01–1.44)
70–80 71.6% (n = 154) 65.4% (n = 83) 1.10 (0.95–1.28)
80–90 73.2% (n = 52) 86.7% (n = 39) 0.85 (0.70–1.01)
all (0–100) 62.1% (n = 551) 52.3% (n = 321) 1.19 (1.09–1.30)
England
40–50 10.1% (n = 34) 10.2% (n = 31) 0.99 (0.62–1.59)
50–60 9.9% (n = 73) 8.9% (n = 60) 1.11 (0.80–1.55)
60–70 11.6% (n = 147) 7.6% (n = 91) 1.53 (1.20–1.98)
70–80 17.4% (n = 247) 11.6% (n = 180) 1.50 (1.26–1.80)
80–90 23.2% (n = 124) 26.2% (n = 213) 0.89 (0.73–1.07)
all (0–100) 14.9% (n = 668) 13.1% (n = 626) 1.14 (1.03–1.26)
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results if unreliable tests were excluded (see Supplemental
Material 1). Similarly, it would be reasonable to ask
whether the greater severity of VF loss may be due to
greater degree of cataract in Tanzania. However, the pat-
tern of results was unchanged if Tanzanian patients with
additional recorded ophthalmic conditions were removed
(see Supplemental Material 1), or when an alternative
method for staging VF loss severity was used, designed to
be less affected by cataract (see Supplemental Material 2).
A second concern is that VF loss at presentation was
quantified by a single perimetric examination, and
individual VF measurements are known to be highly
variable. Thus, it is common for the first examination
to systematically underestimate MD by an average of
2–3 dB32, and there is a similar magnitude of random
error associated with any single measurement of MD.33
Such measurement error is unlikely to have had any
substantial impact on the present findings, however,
due to the size of the effects observed (e.g., the mean
difference in VF loss between Tanzania and England
was over 12 dB). Furthermore, the pattern of results
was unchanged if we instead analyzed data from
patients’ second appointment, or if we excluded less
reliable tests (see Supplemental Material 1).
One key limitation is that the study only considers data
retrospectively. We had no control over how data were
collected, and it is possible that in some cases vision loss
was so severe that VF testing was not even attempted.
Furthermore, some relevant information was not avail-
able. For example, we had no access to information
regarding ethnicity or socioeconomic factors, and we
were unable to corroborate the functional data with struc-
tural measures such as intraocular pressure or optic nerve
appearance. In the UK dataset, clinical diagnoses were
also unavailable, and it is possible that some non-
glaucomatous individuals were included (e.g., those with
neurological disorders) – although the practice of only
including patients with serial VF assessments should have
excluded the majority of such cases. Finally, it is impor-
tant to note that this study was undertaken to determine
the severity of VF loss in individuals presenting to glau-
coma clinics. It was not intended to be a population-based
study and, therefore, we are unable to comment on the
prevalence of glaucoma, or on the number of people who
are failing to enter the health-care system altogether.
Late presentation: causes and solutions
What is driving the high proportions of late presentation
observed, and how could glaucoma detection be improved?
The present data do not allow us to answer these questions
directly; however, previous studies have identified
a number of risk factors for late presentation. These
include: (i) lack of regular eye-checks34,35; (ii) poverty5
(either directly, due to lack of capacity to attend appoint-
ments, or indirectly, through a lack of education), and (iii)
a lack of support36 (both logistical and emotional). These
problems are likely to be universal, but may be exacerbated
in Tanzania by negative perceptions regarding surgical
treatments37,38,39, and by its more geographically sparse
population combined with fewer community-based opto-
metrists – the primary referral route for patients in most
Western countries.40,41 The large proportion of very severe
presenting cases in Tanzania may also represent the addi-
tional challenge posed by a large backlog of cases, which
has built up with an aging population in combination with
limited glaucoma services.
As has been suggested previously by others22,42, one
likely way to improve the early detection of glaucoma –
in both England and Tanzania – would be to increase
routine eye-checks at primary-care facilities located close
to where patients live (e.g., local health centers or high
street opticians). Achieving this in Tanzania may require
additional service provision. In this respect, our findings
are consistent with long-standing calls for “the re-
allocation of resources: from curative to preventive, and
from tertiary and secondary hospitals to dispensaries and
health centres”.43,44 However, provision is only one side
of the equation, and improving public engagement with
existing services is a key challenge in all countries. In this
respect, it was striking that in England the proportion of
individuals presenting late – while lower than in
Tanzania – was nevertheless substantial, with 14% of
individuals exhibiting advanced or severe VF loss.
Given that many English citizens already have local
access to free eye-care services45, this highlights that
service provision alone is insufficient, and that more
also needs to be done to promote engagement with
existing eye-care services; e.g., through education, incen-
tives, and/or the removal of impediments – real or
perceived.46-52 Many people in England, for example,
are unaware that attending an eye-test does not obligate
the purchase of expensive spectacles53,54, or that eye-
testing should be performed regularly, even if not experi-
encing obvious symptoms or difficulties.55
Finally, a comprehensive solution to the problem of late-
presentationmay also require amore proactive approach to
glaucoma case-finding. This has not proven successful in
the past. For example, studies have repeatedly found that
mass screening by traditional methods is too inaccurate or
too expensive to be cost-effective.56-60 However, we are
encouraged by recent technological developments, such as
handheld-OCT61-63 and rebound tonometry64,65, as well as
by attempts to repurpose already ubiquitous technologies
for ophthalmic purposes, such as smartphone fundus
imaging66,67 and tablet tests of visual function.68-77 These
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new portable technologies may be particularly well suited
for use in those more rural communities of Sub-Saharan
Africa. However, to date, studies regarding their efficacy in
practice remain ongoing.
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